胰腺癌
疾病
医学
生物信息学
药物开发
癌症
胰腺导管腺癌
生物
病理
内科学
药品
药理学
作者
Paweł K. Mazur,Alexander Herner,Florian Neff,Jens T. Siveke
出处
期刊:Methods in molecular biology
日期:2015-01-01
卷期号:: 185-215
被引量:9
标识
DOI:10.1007/978-1-4939-2297-0_9
摘要
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in the Western world. The disease has the worst prognosis in the gastrointestinal malignancies with an overall 5-year survival rate of less than 5 %. Therefore, in the search for novel therapeutic targets, biomarkers for early detection and particularly adequate methods to develop and validate therapeutic strategies for this disease are still in urgent demand. Although significant progress has been achieved in understanding the genetic and molecular mechanisms, most approaches have not yet translated sufficiently for better outcome of the patients. In part, this situation is due to inappropriate or insufficient methods in modeling PDAC in laboratory settings. In the past several years, there has been an explosion of genetically engineered mouse models (GEMM) and patient-derived xenografts (PDX) that recapitulate both genetic and morphological alterations that lead to the development of PDAC. Both models are increasingly used for characterization and validation of diagnostic and therapeutic strategies. In this chapter we will discuss state-of-the-art models to consider when selecting an appropriate in vivo system to study disease etiology, cell signaling, and drug development.
科研通智能强力驱动
Strongly Powered by AbleSci AI